Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR
transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V
mutation and HLA-A*11:01 allele. The theoretical basis of this study is that mutant KRAS
antigen-specific TCR transduced autologous Tcells will target and kill HLA-matched mutant
KRAS cancer cells but not normal cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Changhai Hospital Guo ShiWei
Collaborator:
Providence Cancer Center, Earle A. Chiles Research Institute